Navigation Links
Breast Cancer Survivors and Patients Encouraged to Have Medical History Readily Available
Date:10/14/2009

ST. PETERSBURG, Fla., Oct. 14 /PRNewswire/ -- In the United States, a woman is diagnosed with breast cancer every three minutes, according to the American Cancer Society. Except for skin cancers, breast cancer is the most frequently diagnosed cancer among woman.

To help fight this disease, eMed-ID, the world's first emergency medical information device franchise, will donate $10 for every pink Personal Health Records (PHR) wristband sold to raise awareness during Breast Cancer Awareness Month. This pink wristband, as well as other optional styles, contains a USB device that has an individual's personal health history, medications taken, allergies, etc. eMed-ID's proprietary device is designed to expedite emergency responders' treatment of a patient who may not be able to communicate their personal medical information. It also helps consolidate health records and make them accessible to healthcare providers when needed.

"Individuals with breast cancer, as well as survivors of breast cancer, find themselves seeing numerous physicians and managing multiple medications and courses of treatment throughout their illness and beyond," said Lonnie Helgerson, CEO, eMed-ID Franchising, LLC. "As a result, we believe strongly that this group of individuals should have their personal health records consolidated and with them on e-Med-ID's PHR device in case of emergency or other circumstances that require medical history at the ready."

The eMed-ID package is $69.95 and includes the PHR USB device, four eMed-ID caregiver cards, two eMed-ID In Case of Emergency (I.C.E.) refrigerator cards and a bound report. In addition, eMed-ID is the only medical identification product that also provides customers with an optional legally-binding healthcare surrogate, HIPAA release and living will. The company also partners with the "Silver Alert" program, modeled after "Amber Alert," to help protect an increasing number of citizens with cognitive impairments. The pink wristband is just one option. Others include blue wristbands, credit cards and keychains.

"We are honored to join the fight on breast cancer and contribute a portion of the sales of our popular pink wristbands to breast cancer research," said Helgerson. "We've built the eMed-ID business to provide local communities, including people of all ages, with medical services and products that improve the quality of healthcare and save lives. This is just another way to become involved in the health care community and help individuals and families manage their own health."

Consumers can purchase the eMed-ID pink wristband, as well as other products, through eMed-ID's franchise network in cities located throughout the United States. To find your eMed-ID representative, visit www.emed-id.com/find.htm or call 1-866-607-0411.

For those interested in starting their own business, eMed-ID represents an ideal franchise opportunity given the current economic conditions by providing interested franchisees a low-cost of entry. The company is offering candidates the opportunity with a total investment of less than $10,000. Three-year term financing is available to qualified candidates for approximately $38 a week.

Area Representative opportunities are available starting at $29,950 to those interested in recruiting franchisees and owning a minimum protected territory of 200,000 residents. In addition, the franchise provides Veterans a $2,450 discount and a three percent reduction on financing interest.

About eMed-ID

Headquartered in St. Petersburg, FL, eMed-ID is the world's first emergency medical device franchise currently with 22 franchisees operating in several states including Florida, Indiana, Texas, Oregon, Arizona, North Carolina and Montana. The home-based, low cost franchise offers consumers a suite of emergency medical devices to protect their family and friends. For additional product or franchising information, please call 866.607.0411 or log onto www.eMed-ID.com.

    Media Contact:
    Kim Ryan
    Fish Consulting
    770.932.0695
    kryan@fish-consulting.com

SOURCE eMed-ID


'/>"/>
SOURCE eMed-ID
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
7. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
8. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
11. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical (AVACEN) ... is now successfully helping those with the widespread pain ... Fibromyalgia diagnosed Amanda in Essex, England ... washing my hair, experiencing no sleep at all, tremendous ... spasm… I cannot recommend [the AVACEN 100] enough, how ...
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
Breaking Medicine News(10 mins):